Loading…
Loading grant details…
| Funder | Vinnova |
|---|---|
| Recipient Organization | Oxaz Bioactive Ab |
| Country | Sweden |
| Start Date | May 01, 2021 |
| End Date | Dec 29, 2023 |
| Duration | 972 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | Swedish Research Council |
| Grant ID | 2021-00778_Vinnova |
Purpose and goal: ** Denna text är maskinöversatt **
Each year, more than 500 million people in tropical and subtropical regions are infected by disease-spreading mosquitoes, leading to large economic losses and several hundred thousand deaths, mainly among children. Climate change and globalization have led to an increased risk even for people in other areas of being exposed to mosquito-borne infectious diseases.
Our company develops safe and resistance-breaking active ingredients (AIs) aimed at protecting people against mosquito-borne diseases such as malaria, dengue and Zika. Expected results and effects: ** Denna text är maskinöversatt **
Våra AIs has been developed specifically for mosquito control and with a strong focus on safety for other organisms. Våra AIs has a different mode-of-action than today´s insecticides and is effective on Anopheles (malaria) and Aedes (virus) mosquitoes, but is safe for important pollinators. They also show good potential for patenting and regulatory approval and a low risk of mutagenicity or contact allergy.
Approach and implementation: ** Denna text är maskinöversatt **
We are now continuing our commercialization process by verifying efficacy on resistant mosquitoes, safety in mammals (oral toxicity) and potential to protect against other disease-spreading insects (sandflies). Together with ongoing business development, these activities are value-enhancing and necessary preparations to be able to raise capital and build relationships with future partners/takers.
Oxaz Bioactive Ab
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant